SavedAdd your journal

Journals / Medical Network Klinik Bilimler ve Doktor / 2002 / Cilt: 8 - Sayı: 1

Evaluation of relationship between serum IGF-I, IGFBP-3 and growth rate with iron treatment in children with iron deficiency anemia

Demir eksikliği anemili çocuklarda demir tedavisi ile IGF-I, IGFBP-3 düzeyleri ve büyüme hızı arasındaki ilişkinin değerlendirilmesi

Olgu HALLIOĞLU
A. Kemal TOPALOĞLU
Ali CANIM
Öznur DÜZOVALI
Esat YILGÖR
Pages
80–83
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although iron treatment significantly increased BMI levels, a lack of association between iron treatment and serum IGF-I and IGFBP-3 levels suggests that other mechanisms which are not related to IGF-I and IGFBP-3 may play a role on growth.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Insulin like growth factor-I (IGF-I) and insulin like growth factor binding protein-3 (IGFBP-3) are reliable parameters that show growth hormone's (GH) effect.
📊
Key Findings & Data:One of the well known clinical features of iron deficiency anemia is poor appetite and iron supplement in children with iron deficiency anemia results in a faster growth rate.
💡
Conclusion & Impact:Although iron treatment significantly increased BMI levels, a lack of association between iron treatment and serum IGF-I and IGFBP-3 levels suggests that other mechanisms which are not related to IGF-I and IGFBP-3 may play a role on growth.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Somatotropin · Çocuk · Vücut kitle indeksi

Abstract

Insulin like growth factor-I (IGF-I) and insulin like growth factor binding protein-3 (IGFBP-3) are reliable parameters that show growth hormone's (GH) effect. One of the well known clinical features of iron deficiency anemia is poor appetite and iron supplement in children with iron deficiency anemia results in a faster growth rate. However, mechanism of this process has not yet been established. The objective of this study was to examine the relationship between serum IGF-I, IGFBP-3 and growth rate with iron treatment in children with iron deficiency anemia. In 28 infants and small children (mean age: 19.0 ± 8.7 month) with iron deficiency, we studied serum IGF-I and IGFBP-3 levels before and after iron therapy. After 15 ± 2.4 weeks of iron treatment, serum hemoglobin levels (p<0.001), ferritin (p<0.001) levels and body mass index (BMI) (p<0.05) significantly increased when serum IGF-I and IGFBP-3 levels were unchanged. Serum IGF-I and IGFBP-3 levels were significantly correlated with each other (r: 0.807 p<0.001) and BMI (IGF-I r:0.39 p<0.05 ; IGFBP-3 r: 0.52 p<0.01). Although iron treatment significantly increased BMI levels, a lack of association between iron treatment and serum IGF-I and IGFBP-3 levels suggests that other mechanisms which are not related to IGF-I and IGFBP-3 may play a role on growth.

Özet

İnsülin like growth faktör-I (IGF-I) ve insülin like growth faktör binding protein-3 (IGFBP-3) growth hormonun (GH) etkisini iyi gösteren parametrelerdir. Demir eksikliği anemisi çocuklarda iştahsızlık ile giden klinik durumlardan birisidir ve tedavi ile büyümenin hızlandığı gösterilmiştir. Ancak bu olayın mekanizması aydınlatılamamıştır. Bu çalışmanın amacı, demir eksikliği anemisi olan çocuklarda tedavi ile IGF-I ve IGFBP-3 düzeyleri ve büyüme hızı arasındaki ilişkileri araştırmaktı. Demir eksikliği anemisi olan 28 hasta (yaş: 19.0 ± 8.7 ay) çalışmaya alındı, tedavi öncesinde ve sonrasında serum IGF-I, IGFBP-3 düzeyleri çalışıldı. 15.0 ± 2.4 haftalık demir tedavisinden sonra hastanın hemoglobin (p<0.001), ferritin (p<0.001)düzeyleri ve vücut kitle indeksinde (BMI) (p<0.05) anlamlı bir artış gözlenirken, IGF-I ve IGFBP-3 düzeylerinde istatistiksel anlamlı bir fark gözlenmedi. IGF-I ve IGFBP-3 düzeyleri kendi aralarında (r: 0.807 p<0.001) ve BMI (IGF-I r: 0.39 p<0.05 ; IGFBP-3 r: 0.52 p<0.01) ile korele idi. Demir tedavisi ile hastaların BMI düzeylerinde belirgin artma saptandığı halde IGF-I ve IGFBP-3 düzeylerinde anlamlı bir artış olmaması, büyüme üzerinde IGF-I ve IGFBP-3'den bağımsız mekanizmaların da rol oynadığını düşündürdü.

🔖

Cite This Article

HALLIOĞLU, O., TOPALOĞLU, A. K., CANIM, A., DÜZOVALI, Ö., YILGÖR, E. (2002). Evaluation of relationship between serum IGF-I, IGFBP-3 and growth rate with iron treatment in children with iron deficiency anemia. Medical Network Klinik Bilimler ve Doktor, Cilt: 8 - Sayı: 1, 80–83. https://ajindex.com/articles/279177

References (9)

  1. Yakar J, Liu J, Le Roith D. The growth hormone/insulin-like growth factor-1 system: implications for organ growth and development. Pediatr Nephrol 2000; 14:544-549.
  2. Collett-Solberg PF, Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am 1996; 25:591-614. Preece MA. Making a rational diagnosis of growth-hormone deficiency. J Pediatr 1997; 131(1 Pt2):S61-64. Brabin BJ, Premji Z, Verhoeff F. An analysis of anemia and child mortality. J Nutr 2001; 131(2S-2):636S-645S. Wharton B. Taste and appetite in infancy: possible topics for research. Pediatrics 2000; 106:1278A-1278. Aukett MA, Parks YA, Scott PH, Wharton BA. Treatment with iron.; increases weight gain and psychomotor development. Arch Dis Child 1986: 61:849-857.
  3. Angeles IT, Schultink WJ, Matulessi P, Gross R, Sastroamidjojo S. Decreased rate of stunting among anemic Indonesian preschool children through iron supplementation. Am J Clin Nutr 1993; 58:339-342.
  4. Sherriff A, Emond A, Hawkins N. Golding J. Haemoglobin and ferritin concentrations in children aged 12 and 18 months. ALSPAC Children in Focus Study Team. Arch Dis Child 1999; 80: 153-157.
  5. Makitie O, Juvonen E, Dunkel L, Kaitila I, Siimes MA. Anemia in children with cartilage-hair hypoplasia is related to body growth and to the insulin-like growth factor system. J Clin Endocrinol Metab 2000; 85:563-568.
  6. Low LC, Postel-Vinay MC, Kwan EY, Cheung PT. Serum growth hormone (GH) binding protein, IGF-I and IGFBP-3 in patients with beta-thalassaemia major and the effect, of GH treatment. Clin Endocrinol (Oxf) 1998; 48:641- 646. Hintz RL, Suskind R, Amatayakul K, Thanangkul O, Olson R. Plasma somatomedin and growth hormone values in children with protein-calorie malnutrition. J Pediatr 1978; 92:153-156.
  7. Soliman AT, Hassan AE, Aref MK, Hintz RL, Rosenfeld RG, Rogol AD. Serum insulin-like growth factors I and II concentrations and growth hormone and insulin responses to arginine infusion in children with protein- energy malnutrition before and after nutritional rehabilitation. Pediatr Res 1986; 20:1122-1130.
  8. Herington AC, Werther GA, Mathews RN, Burger HG. Studies on the possible mechanism for deficiency of nonsuppressible insulin-like activity in thalassemia major. J Clin Endocrinol Metab 1981; 52:393-398.
  9. Kwan EY, Lee AC, Li AM, et al. A cross-sectional study of growth, puberty and endocrine function in patients with thalassaemia major in Hong Kong. J Paediatr Chil